NCT06703047View on ClinicalTrials.gov

Tislelizumab Combined with Chemotherapy and All Trans Retinoic Acid for Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

November 20, 2024

Primary Completion Date

November 20, 2029

Study Completion Date

October 24, 2030

Conditions
Esophageal Squamous Cell Carcinoma
Interventions
DRUG

ATRA+pd-1+chemo

All trans tretinoic acid+tislelizumab+chemotherapy (paclitaxel, cisplatin, or carboplatin)

DRUG

placebo+PD-1+chemo

Placebo+tislelizumab+chemotherapy (paclitaxel, cisplatin, or carboplatin)

All Listed Sponsors
lead

Fudan University

OTHER

NCT06703047 - Tislelizumab Combined with Chemotherapy and All Trans Retinoic Acid for Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma | Biotech Hunter | Biotech Hunter